Precision medicine is like a smart bomb that bases treatment on a patient's individual genetics. One company makes the hardware and software to help make it happen.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
U.S. District Judge Vince Chhabria said that he would have a final ruling by the end of next week.
The Senator says that Gottlieb's appointment to the company's board smacks of the Washington revolving door that has become prevalent.
Shares of Pfizer rise after the company announces positive results in a late-stage, non-steroid trial of a treatment for chronic dermatitis, or eczema, in kids.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.